z-logo
open-access-imgOpen Access
Comparison of phenotyping and genotyping of lymphoid neoplasms
Author(s) -
Sun Tsieh,
Eisenberg Arthur,
Benn Peter,
Ngu Mei,
Guarino Theresa,
Henshall Joan,
Grossman Abraham,
Cuomo Joanne,
Vinciguerra Vincent
Publication year - 1989
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860030305
Subject(s) - lymphoma , genotyping , monoclonal , monoclonal antibody , microbiology and biotechnology , biology , population , pathology , flow cytometry , gene rearrangement , bone marrow , gene , antibody , cancer research , genotype , immunology , medicine , genetics , environmental health
Abstract Comparison of phenotyping (PT) and genotyping (GT) of lymphoid neoplasms was performed on 51 specimens including lymph nodes, bone marrows, and body fluids. PT was performed with a flow cytometer using a large monoclonal antibody panel. GT included the testing for gene rearrangements of heavy chain, κ and λ light chains, and T‐cell receptor β‐chain genes with DNA probes. The results obtained from these two techniques were generally compatible in terms of clonality and cell lineage. Only one case of B‐cell lymphoma was not diagnosed by PT but showed gene rearrangement. For T‐cell lymphoma, GT offers a more definitive diagnosis than does PT. Biclonality was demonstrated in one case of hairy cell leukemia by GT only. The rearranged band also offers a definitive clonal identification based on electrophoretic mobility. GT can detect a monoclonal population as small as 5% and can be performed on old or fresh specimens. PT requires 20% abnormal cells and a fresh specimen. It is concluded that GT is superior to PT for lymphoid tumor diagnosis, but it should be reserved as a supplementary test at this stage because of its technical complexity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here